Edward P Evans Foundation

January 4, 2024

Potential AML therapy induces leukemic stem cell death

Vanderbilt researchers are studying a potential therapy for acute myeloid leukemia that targets the residual leukemic stem cells in bone marrow after treatment that are responsible for relapses and drug resistance.

By Tom Wilemon
August 29, 2022

Blood cancer progression

Vanderbilt researchers used single-cell technologies to explore the accumulation of mutations during blood cancer progression, which could help identify strategies for preventing leukemia before it occurs.

By Leigh MacMillan
January 27, 2022

Impaired neutrophils in autoimmunity

Vanderbilt researchers help answer the question of why patients with autoimmune diseases like lupus are more susceptible to bacterial infections: their neutrophils have impaired antibacterial activity.

By Leigh MacMillan
September 10, 2021

Caught in a web: study reveals that immune cells cooperate to trap and kill bacteria

Vanderbilt researchers have identified a new antibacterial mechanism that could inspire novel strategies for combating staph and other extracellular bacterial pathogens.

By Leigh MacMillan
January 21, 2021

WIN for blocking cancer growth

William Tansey and colleagues identified proteins that interact with the cancer drug target WDR5 and are important for cancer cell growth.

By Sarah E. Glass
red and blue boxing gloves
March 5, 2020

One-two punch for cancer

A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients.

By Sanjay Mishra
August 1, 2019

Grant bolsters research on myelodysplastic syndromes

Michael Savona, MD, has received a competitive grant to develop therapies for patients with myelodysplastic syndromes.
By Tom Wilemon
January 31, 2019

Cell death pathway implicated in bone marrow failure

Vanderbilt investigators have linked a specific form of programmed cell death to myelodysplastic syndrome, a type of bone marrow failure.
By Leigh MacMillan
October 2, 2015

The yin and yang of COX-2

New findings add to the understanding of how the enzyme COX-2 works, which is critical to the development of COX-2-targeted anti-inflammatory drugs.
By Sanjay Mishra